In 2025, a variety of health stories unfolded, including the approval of a new drug for postpartum depression and innovative genetic therapies for rare diseases. Looking ahead to 2026, the CBC Health Unit is monitoring several key areas, such as new strategies for connecting individuals with family physicians, anticipated adjustments to cancer screening protocols, concerns surrounding misinformation and vaccine hesitancy, potential future applications of GLP-1 agonists like Ozempic and Wegovy, and the evolving challenges of the toxic drug crisis.
Addressing the ongoing issue of doctor shortages, a recent survey revealed that nearly six million Canadian adults lack a regular family physician. To combat this problem, Colwood, a city near Victoria in British Columbia, introduced a unique solution by offering doctors municipal employment status. This initiative provides doctors with benefits such as a salary, pension, and improved work-life balance. The Colwood clinic, which opened this year, has already recruited three physicians with plans to hire five more by 2030. This innovative approach is gaining attention nationwide, inspiring other municipalities and healthcare organizations to consider similar models.
The Canadian Task Force on Preventive Health Care, responsible for issuing national cancer screening guidelines, is undergoing a significant reorganization following external scrutiny and a temporary pause in its operations by the federal health minister. The review highlighted the need for updated guidelines, particularly in areas like breast cancer screening. The task force is currently working on implementing recommendations from the review and is expected to reconvene in April 2026 to prioritize various health topics.
The resurgence of vaccine-preventable diseases globally, including Canada losing its measles elimination status and declining vaccination rates, has raised concerns. Misinformation, vaccine hesitancy, and political influences continue to impact vaccination efforts, with notable policy changes observed in the U.S. that may influence public perception in Canada. Recent polling indicates a decline in Canadians’ confidence in vaccines, emphasizing the importance of addressing these challenges to maintain public health and prevent the resurgence of preventable diseases.
Looking ahead to 2026, developments related to the diabetes drug Ozempic are anticipated, with potential approvals for generic versions expected following the expiration of its patent in Canada. The availability of cheaper alternatives could significantly impact accessibility to this medication, with potential implications for its off-label uses in treating obesity. Ongoing research on semaglutide drugs like Ozempic for various health conditions, such as addiction and heart disease, presents both opportunities and challenges in the medical field.
Amid ongoing efforts to combat the illegal drug supply crisis in Canada, medical officers of health have reported a decline in daily deaths attributed to toxic drugs, although challenges persist due to the changing nature of the illicit drug market. Monitoring these trends and addressing emerging substances remains a priority to mitigate the impact on communities and prevent further loss of life.